Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group

Excerpt from the Press Release:

• Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form of cancer –

• Affinia Therapeutics to use its proprietary technologies and capsids with improved properties to bring the promise of gene therapy to patients with rare and prevalent devastating diseases –
  
• To support clinical supply, Affinia Therapeutics has entered into a multi-year strategic manufacturing agreement with Lonza Group, a founding investor –
  

WALTHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) capsids developing gene therapies for rare and prevalent devastating diseases, today announced the first two indications it will pursue with its next-generation gene therapies: metachromatic leukodystrophy (MLD), a rare, progressive, and fatal neurodegenerative disease, and brain metastases secondary to human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BMBC), a common and deadly form of cancer. The company’s therapeutic candidates for these two indications are directed at targets in the central nervous system (CNS) and are based on its proprietary capsid, Anc80L65, which when delivered intrathecally has been observed to be 40-times more efficient at delivering genetic payloads to regions of the brain than AAV9, a capsid used by others in the field for CNS-directed gene therapies.

Click the button below to read the entire Press Release:

Continue Reading The Press Release